Triple-negative breast cancers: Unique clinical presentations and outcomes

Annals of Surgical Oncology

Volumn 17, Issue SUPPL. 3, 2010, Pages

  Billar, Julie A Y ^a   Dueck, Amylou C ^a   Stucky, Chee Chee H ^a   Gray, Richard J ^a   Wasif, Nabil ^a   Northfelt, Donald W ^a   McCullough, Ann E ^a   Pockaj, Barbara A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; BREAST CANCER; BREAST EXAMINATION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CONFERENCE PAPER; FEMALE; GENETIC SCREENING; GROUPS BY AGE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT REFERRAL; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78149256247     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1260-4     Document Type: Conference Paper

References (45)

1. O Gluz C Liedtke N Gottschalk L Pusztai U Nitz N Harbeck 2009 Triple-negative breast cancer-current status and future directions Ann Oncol. 20 1913 1927 1:STN:280:DC%2BD1MjnsVGjug%3D%3D 10.1093/annonc/mdp492 19901010
2. SC Linn LJ Van't Veer 2009 Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept Eur J Cancer 45 Suppl 1 11 26 10.1016/S0959-8049(09)70012-7 19775601
3. SJ Dawson E Provenzano C Caldas 2009 Triple negative breast cancers: clinical and prognostic implications Eur J Cancer 45 Suppl 1 27 40 10.1016/S0959-8049(09)70013-9 19775602
4. C Sotiriou L Pusztai 2009 Gene-expression signatures in breast cancer N Engl J Med. 360 790 800 1:CAS:528:DC%2BD1MXitFWqs70%3D 10.1056/NEJMra0801289 19228622
5. CM Perou T Sørlie MB Eisen M van de Rijn SS Jeffrey CA Rees, et al. 2000 Molecular portraits of human breast tumours Nature. 406 747 752 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
6. T Sørlie CM Perou R Tibshirani T Aas S Geisler H Johnsen, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A. 98 10869 10874 10.1073/pnas.191367098 11553815
7. C Sotiriou SY Neo LM McShane EL Korn PM Long A Jazaeri, et al. 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci U S A. 100 10393 10398 1:CAS:528:DC%2BD3sXntFynsrk%3D 10.1073/pnas.1732912100 12917485
8. KD Voduc MC Cheang S Tyldesley K Gelmon TO Nielsen H Kennecke 2010 Breast cancer subtypes and the risk of local and regional relapse J Clin Oncol. 28 1684 1691 10.1200/JCO.2009.24.9284 20194857
9. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A. 100 8418 8423 1:CAS:528:DC%2BD3sXlsFGntLk%3D 10.1073/pnas.0932692100 12829800
10. LA Carey CM Perou CA Livasy LG Dressler D Cowan K Conway, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA. 295 2492 2502 1:CAS:528:DC%2BD28XlsV2rtLw%3D 10.1001/jama.295.21.2492 16757721
11. C Lin SY Chien LS Chen SJ Kuo TW Chang DR Chen 2009 Triple negative breast carcinoma is a prognostic factor in Taiwanese women BMC Cancer. 9 192 10.1186/1471-2407-9-192 19534825
12. R Dent M Trudeau KI Pritchard WM Hanna HK Kahn CA Sawka, et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res. 13 4429 4434 10.1158/1078-0432.CCR-06-3045 17671126
13. A Spitale P Mazzola D Soldini L Mazzucchelli A Bordoni 2009 Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland Ann Oncol. 20 628 635 1:STN:280:DC%2BD1M3jt1aqtQ%3D%3D 10.1093/annonc/mdn675 19074747
14. BG Haffty Q Yang M Reiss T Kearney SA Higgins J Weidhaas, et al. 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol. 24 5652 5657 10.1200/JCO.2006.06.5664 17116942
15. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687-717.
16. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med. 353 1659 1672 1:CAS:528:DC%2BD2MXhtFansr3L 10.1056/NEJMoa052306 16236737
17. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med. 353 1673 1684 1:CAS:528:DC%2BD2MXhtFansr3F 10.1056/NEJMoa052122 16236738
18. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett, et al. 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet. 369 29 36 1:CAS:528:DC%2BD2sXit12itg%3D%3D 10.1016/S0140-6736(07)60028-2 17208639
19. AC Wolff MEH Hammond JN Schwartz KL Hagerty DC Allred RJ Cote, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol. 25 118 145 1:CAS:528:DC%2BD2sXht1ejs7Y%3D 10.1200/JCO.2006.09.2775 17159189
20. NU Lin A Vanderplas ME Hughes RL Theriault SB Edge Y Wong, et al. 2009 Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer network (NCCN) J Clin Oncol 27 suppl; abstr 543 543
21. K Collett IM Stefansson J Eide A Braaten H Wang GE Eide, et al. 2005 A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors Cancer Epidemiol Biomarkers Prev. 14 1108 1112 1:CAS:528:DC%2BD2MXktFCksLg%3D 10.1158/1055-9965.EPI-04-0394 15894660
22. FD Gilliland N Joste PM Stauber WC Hunt R Rosenberg G Redlich, et al. 2000 Biologic characteristics of interval and screen-detected breast cancers J Natl Cancer Inst. 92 743 749 1:STN:280:DC%2BD3c3lsFersQ%3D%3D 10.1093/jnci/92.9.743 10793111
23. DS Tan C Marchió RL Jones K Savage IE Smith M Dowsett, et al. 2008 Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients Breast Cancer Res Treat. 111 27 44 1:CAS:528:DC%2BD1cXos1Wnsbs%3D 10.1007/s10549-007-9756-8 17922188
24. H Wang N Bjurstam H Bjørndal A Braaten L Eriksen P Skaane, et al. 2001 Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT Int J Cancer. 94 594 598 1:CAS:528:DC%2BD3MXns1Gnu70%3D 10.1002/ijc.1511 11745450
25. S Basu W Chen J Tchou A Mavi T Cermik B Czerniecki, et al. 2008 Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography using parameters: a potentially useful method for disease characterization Cancer. 112 995 1000 1:CAS:528:DC%2BD1cXjs1eqsLo%3D 10.1002/cncr.23226 18098228
26. JH Chen RS Mehta PM Carpenter O Nalcioglu MY Su 2007 Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy J Clin Oncol. 25 5667 5669 10.1200/JCO.2007.14.6134 18065744
27. SE Singletary C Allred P Ashley LW Bassett D Berry KI Bland, et al. 2002 Revision of the American Joint Committee on Cancer staging system for breast cancer J Clin Oncol. 20 3628 3636 10.1200/JCO.2002.02.026 12202663
28. WD Foulkes MJ Grainge EA Rakha AR Green IO Ellis 2009 Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status Breast Cancer Res Treat. 117 199 204 10.1007/s10549-008-0102-6 18600446
29. R Dent WM Hanna M Trudeau E Rawlinson P Sun SA Narod 2009 Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status Cancer. 115 4917 4923 10.1002/cncr.24573 19691094
30. GM Freedman PR Anderson T Li N Nicolaou 2009 Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation Cancer. 115 946 951 10.1002/cncr.24094 19156929
31. EK Millar PH Graham SA O'Toole CM McNeil L Browne AL Morey, et al. 2009 Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel J Clin Oncol. 27 4701 4708 10.1200/JCO.2008.21.7075 19720911
32. PL Nguyen AG Taghian MS Katz A Niemierko RF Abi Raad WL Boon, et al. 2008 Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol. 26 2373 2378 10.1200/JCO.2007.14.4287 18413639
33. LJ Solin WT Hwang N Vapiwala 2009 Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma Clin Breast Cancer. 9 96 100 10.3816/CBC.2009.n.018 19433390
34. BD Smith DW Arthur TA Buchholz BG Haffty CA Hahn PH Hardenbergh, et al. 2009 Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) Int J Radiat Oncol Biol Phys. 74 987 1001 19545784
35. J Hugh J Hanson MC Cheang TO Nielsen CM Perou C Dumontet, et al. 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Clin Oncol. 27 1168 1176 1:CAS:528:DC%2BD1MXktFKhs7Y%3D 10.1200/JCO.2008.18.1024 19204205
36. EA Comen M Robson 2010 Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer Cancer J. 16 48 52 1:CAS:528:DC%2BC3cXjvVKktL8%3D 10.1097/PPO.0b013e3181cf01eb 20164690
37. PC Fong DS Boss TA Yap A Tutt P Wu M Mergui-Roelvink, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med. 361 123 134 1:CAS:528:DC%2BD1MXosVKrtrw%3D 10.1056/NEJMoa0900212 19553641
38. B Corkery J Crown M Clynes N O'Donovan 2009 Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Ann Oncol. 20 862 867 1:STN:280:DC%2BD1MzgvVyitw%3D%3D 10.1093/annonc/mdn710 19150933
39. RS Finn J Dering C Ginther CA Wilson P Glaspy N Tchekmedyian, et al. 2007 Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat. 105 319 326 1:CAS:528:DC%2BD2sXhtFSlsr3N 10.1007/s10549-006-9463-x 17268817
40. F Dantzer G de La Rubia J Ménissier-De Murcia Z Hostomsky G de Murcia V Schreiber 2000 Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1 Biochemistry. 39 7559 7569 1:CAS:528:DC%2BD3cXjs1Knsbo%3D 10.1021/bi0003442 10858306
41. H Farmer N McCabe CJ Lord AN Tutt DA Johnson TB Richardson, et al. 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. 434 917 921 1:CAS:528:DC%2BD2MXjtFOmsrc%3D 10.1038/nature03445 15829967
42. D Ford DF Easton M Stratton S Narod D Goldgar P Devilee, et al. 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium Am J Hum Genet. 62 676 689 1:CAS:528:DyaK1MXlvFeh 10.1086/301749 9497246
43. D Ford DF Easton DT Bishop SA Narod DE Goldgar 1994 Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium Lancet. 343 692 695 1:STN:280:DyaK2c7otVKitQ%3D%3D 10.1016/S0140-6736(94)91578-4 7907678
44. A Musolino MA Bella B Bortesi M Michiara N Naldi P Zanelli, et al. 2007 BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study Breast. 16 280 292 10.1016/j.breast.2006.12.003 17257844
45. DP Atchley CT Albarracin A Lopez V Valero CI Amos AM Gonzalez-Angulo, et al. 2008 Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer J Clin Oncol. 26 4282 4288 10.1200/JCO.2008.16. 6231 18779615